GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 72
- Registration Number
- NCT04150068
- Locations
- 🇺🇸
Mills Clinical Research, Los Angeles, California, United States
🇺🇸Emory Hospital Midtown Infectious Disease Clinic, Atlanta, Georgia, United States
🇺🇸North Texas Infectious Diseases Consultants, P.A., Dallas, Texas, United States
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV
- Conditions
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 183
- Registration Number
- NCT04143594
- Locations
- 🇺🇸
Howard Brown Health Center, Chicago, Illinois, United States
🇺🇸Northstar Healthcare, Chicago, Illinois, United States
🇺🇸Case Clinical Research Site/University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 19
- Registration Number
- NCT04130919
- Locations
- 🇺🇸
Alliance Medical Research, Coral Springs, Florida, United States
🇺🇸Encore Borland-Groover Clinical Research, Jacksonville, Florida, United States
🇺🇸Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT04115839
- Locations
- 🇨🇦
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc., Quebec, Canada
🇯🇵Keio University Hospital, Tokyo, Japan
🇵🇱Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 67
- Registration Number
- NCT04115748
- Locations
- 🇭🇺
Synexus (DRS) - Synexus Magyarorszag Kft. Budapest, Budapest, Hungary
🇵🇱Centrum Medyczne Pratia Gdynia, Gdynia, Poland
🇵🇱Medycyna Kliniczna Marzena Waszczak-Jeka, Warszawa, Poland
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 37
- Registration Number
- NCT04112303
- Locations
- 🇯🇵
Fukui-ken Saiseikai Hospital, Fukui, Japan
🇯🇵Chiba University Hospital, Chiba, Japan
🇯🇵Iizuka Hospital, Iizuka, Japan
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 11
- Registration Number
- NCT04060147
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
🇺🇸University of California San Francisco, Liver Clinic, San Francisco, California, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT04049617
- Locations
- 🇳🇿
Christchurch Clinical Studies Trust, LLC, Christchurch, New Zealand
🇺🇸NEXT Oncology, San Antonio, Texas, United States
🇳🇿Auckland Clinical Studies Ltd, Grafton, Auckland, New Zealand
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 384
- Registration Number
- NCT04026165
- Locations
- 🇺🇸
North Shore University Hospital: Division of Nephrology, Great Neck, New York, United States
🇺🇸Knoxville Kidney Center, PLLC, Knoxville, Tennessee, United States
🇺🇸Research By Design, LLC, Chicago, Illinois, United States
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 143
- Registration Number
- NCT04009057
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱Kaplan Medical Center, Rehovot, Israel
🇮🇱Tel Aviv Souraski Medical Center, Tel Aviv, Israel